D ual antiplatelet therapy (DAPT) with aspirin and clopidogrel is effective in preventing stent thrombosis and is widely used after percutaneous coronary intervention (PCI). However, the high residual platelet reactivity (high RPR) after DAPT is associated with increased cardiovascular events. 1-3 Several studies have demonstrated that RPR itself is treatable and adjustable by increasing the dose of clopidogrel, 4,5 although aggressive antiplatelet therapy is reported to increase the risk of hemorrhagic events 6,7 and does not always prevent the occurrence of future cardiovascular events. 4, 5, 8 Background-Dual antiplatelet therapy with aspirin and clopidogrel is widely used in patients with coronary stents. High residual platelet reactivity (high RPR) after dual antiplatelet therapy is associated with increased cardiovascular events. Endothelial function could affect platelet reactivity in vivo. We hypothesized that endothelial dysfunction could be associated with high RPR after dual antiplatelet therapy in patients with stable coronary artery disease. Methods and Results-We screened patients with stable coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked CYP2C19*2 or *3 loss-of-function allele to minimize the effect of this gene on high RPR. All patients received aspirin (100 mg/d) and clopidogrel (75 mg/d for long-term treatment or a loading dose of 300 mg) before the following tests. Platelet aggregability was assessed as P2Y12 reaction unit using the VerifyNow System. High RPR was defined as P2Y12 reaction unit ≥230. Peripheral endothelial function was expressed as reactive hyperemia index using reactive hyperemia peripheral arterial tonometry. Fifty-three patients exhibited high RPR. High RPR patients were significantly older, had higher levels of B-type natriuretic peptide, and were predominantly hypertensive compared with non-high RPR patients. Reactive hyperemia index was significantly lower in high RPR patients (0.46±0.15) compared with non-high RPR patients (0.61±0.18; P<0.001). Linear regression analysis demonstrated significant negative correlation between reactive hyperemia index and P2Y12 reaction unit (r=−0.32; P=0.001). Multivariable logistic regression analysis identified reactive hyperemia index as an independent and significant determinant of high RPR (odds ratio, 0.55; 95% confidence interval, 0.39-0.78; P=0.001). Conclusions-In patients with stable coronary artery disease, endothelial function was significantly impaired in high RPR patients. Endothelial dysfunction is independently correlated with high RPR after dual antiplatelet therapy. Clinical Trial Registration-URL: http://www.umin.ac.jp/ctr. Unique identifier: UMIN000008239. (Circ Cardiovasc Interv. 2013;6:452-459.)
The VerifyNow P2Y12 assay (Ultegra rapid platelet function assay; Accumetrics Inc, San Diego, CA) has made it possible to quantify RPR clinically at bedside and identify patients with high RPR. Thus, it is currently possible to provide tailored antiplatelet therapy by using VerifyNow P2Y12 assay.
Clopidogrel is a prodrug activated in the liver by cytochrome P450 (CYP) enzymes. 9 It has been demonstrated that patients with variants in CYP2C19 have lower levels of the active metabolite of clopidogrel with less inhibition of platelet aggregation. [10] [11] [12] However, the majority of Europeans and Americans do not have CYP2C19 reduced-function allele 13, 14 ; it has been reported that high RPR cases are often observed among whites who are not carriers of CYP2C19 reducedfunction allele. Thus, the CYP2C19 gene analysis was not recommended for cardiovascular risk evaluation in the statement published by the American Heart Association. 15 At present, the precise mechanism of high RPR remains obscure, and there is a need to understand the pathogenesis of high RPR especially in patients without CYP2C19 reduced-function allele.
Platelet aggregation is closely associated with the integrity and condition of the vascular endothelium in vivo. 16 Endothelial dysfunction could enhance high RPR through inadequate production of nitric oxide and prostacyclin, which counteract platelet aggregation. 16 The endothelium maintains vascular homeostasis, and endothelial dysfunction is an early marker for atherosclerosis. 17 Because PCI evokes local coronary endothelial injury and patients with coronary artery disease (CAD) usually exhibit endothelial dysfunction, evaluation of platelet aggregability and endothelial function and defining their correlation are no doubt important in CAD patients who undergo PCI. Previous clinical studies indicated that endothelial dysfunction correlated significantly with increased platelet aggregability, 18, 19 but the effects of coronary risk factors and genetic polymorphisms on platelet aggregability and endothelial function have not been determined. Peripheral endothelial function and the therapeutic effectiveness of DAPT can be assessed clinically by the reactive hyperemia index using reactive hyperemia peripheral arterial tonometry (RH-PAT), and by RPR, respectively. The main hypothesis tested in the present study was that peripheral endothelial dysfunction is associated with high RPR in patients with CAD free of genetic polymorphism of CYP2C19*2 or *3 loss-of-function allele.
Methods

Study Population
The study subjects were patients with stable CAD who visited Kumamoto University Hospital between August 2008 and June 2012. CAD was defined as history of angina or myocardial ischemia by stress tests coupled with coronary stenosis of >50% of the vessel diameter detected by coronary angiography or computed tomography coronary angiography scan, or history of myocardial infarction, PCI, or coronary artery bypass grafting. We excluded patients with acute coronary syndrome who required emergency coronary angiography, defined as acute myocardial infarction (with or without electrocardiographic evidence of ST-segment-elevation), those with unstable angina (class II or III of Braunwald classification), or patients with known allergy to clopidogrel or thrombocytopenia (platelet count <10×10 4 /μL). We also excluded patients with collagen disease, infection, severe liver dysfunction, and malignant diseases and patients treated with ticlopidine, cilostazol, and sarpogrelate, and those on hemodialysis. There were no patients treated with n-3 polyunsaturated fatty acids. We identified CYP2C19 genotypes and finally enrolled 103 patients without CYP2C19*2 or *3 loss-of-function allele to minimize the effects of genetics on high RPR (genotype analysis in online-only Data Supplement).
This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Human Ethics Review Committee of Kumamoto University Graduate School of Medicine, and a signed consent form was obtained from each subject. This study was registered at the UMIN protocol registration system with the identification number UMIN000008239.
Study Protocol
At baseline, we measured RPR, peripheral endothelial function, and conducted various laboratory tests, such as high-sensitivity C-reactive protein and B-type natriuretic peptide (BNP), in patients with stable CAD before coronary angiography (blood sampling method in the online-only Data Supplement). RPR was assessed by VerifyNow P2Y12 assay (detail of VerifyNow P2Y12 is given in the online-only Data Supplement). A high P2Y12 reaction unit (PRU) result reflects greater P2Y12-mediated reactivity. High RPR was defined as PRU ≥230. 4 Achievement of on-treatment reactivity of 208 PRU was independently associated with a markedly lower risk of cardiovascular outcomes at 60day follow-up in post hoc analysis of the Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety (GRAVITAS) study. 20 We further divided the whole population into 2 groups by the value of 208 PRU: the non-high RPR 208 group and the high RPR 208 group to identify patients with high RPR after DAPT. Peripheral endothelial function was assessed by RH-PAT index (RHI) using RH-PAT (details of RHI and RH-PAT in the online-only Data Supplement).
All patients were under long-term aspirin treatment (100 mg/d) for >7 days. Fifty patients already received clopidogrel (75 mg/d) for >7 days, and 53 patients were treated with a loading dose of clopidogrel (300 mg) ≥24 hours and subsequent daily 75 mg before the following tests.
Statistical Analysis
The Shapiro-Wilk test was used to assess the normal distribution of continuous data. Data are expressed as mean±SD, whereas those with skewed distributions were expressed as the median value with interquartile range. Categorical data were presented as frequencies and percentages. Differences between 2 groups were tested with Fisher
WhAT IS KNOWN
• High residual platelet reactivity after dual antiplatelet therapy is associated with increased cardiovascular events.
• Patients with variants in cytochrome P450 (CYP) 2C19 have lower levels of the active metabolite of clopidogrel with less inhibition of platelet aggregation.
• Platelet aggregation is closely associated with the integrity and condition of the vascular endothelium in vivo.
WhAT ThE STuDy ADDS
• Peripheral endothelial dysfunction is independently correlated with higher residual platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease who do not carry a CYP2C19 reduced-function allele.
exact test for categorical variables. Differences in continuous variables were analyzed by the unpaired t test or Mann-Whitney U test, as appropriate. Pearson correlation coefficient was used for evaluation of the association between RHI and the parameters of platelet aggregation (PRU). Spearman rank correlation coefficient was used if variables were not normally distributed (the association between RHI and other clinical variables). In this study, the outcome variables for the regression model were RPR values (continuous variable) for the multivariable linear regression model and the high RPR group (dichotomous variable) for the multivariable logistic regression model. Significant clinical parameters associated with PRU in simple (univariate) logistic regression analysis and several factors reported previously to affect platelet reactivity were evaluated by multivariable logistic regression analysis. We used the Kaplan-Meier method to estimate the cardiovascular event probabilities at 1340 days, and we also used the log-rank test to compare distributions of survival times between the high RPR (or high RPR 208 ) group and the non-high RPR (or non-high RPR 208 ) group. A P<0.05 denoted statistical significance. Statistical analyses were performed using SPSS version 20 (SPSS Inc, Tokyo, Japan). An expended Methods section is available in the online-only Data Supplement. Table 1 lists the baseline characteristics of the enrolled patients. Patients of the high RPR group were significantly older, had higher prevalence of hypertension, and had higher levels of BNP compared with the non-high RPR group. RHI was significantly lower in the high RPR group (0.46±0.15) than in the non-high RPR group (0.61±0.18; P<0.001; Figure 1 ).
Results
Clinical Characteristics of Study Population
Correlation Between RhI and PRu
There was a significant negative correlation between RHI and PRU (r=−0.32; P=0.001; Figure 2 ) and a significant positive correlation between RHI and % platelet inhibition (ρ=0.35; P=0.001). BNP also correlated significantly with PRU (ρ=0.34; P=0.001). However, age and hypertension did not correlate with PRU. The multivariable linear regression model consisted of RHI and the variables (age, diabetes mellitus, estimated glomerular filtration rate, and Log 10 [BNP]) that had been independently shown to impact RPR in the previous studies. 18, [21] [22] [23] [24] [25] [26] Each of RHI and BNP was shown as the independently associated factor for RPR ( Table 2 ). Table 3 shows the results of univariate and multivariable logistic regression analyses for high RPR. Simple logistic regression analysis demonstrated that age, prevalence of hypertension, angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin-II receptor blocker (ARB) use, BNP, and RHI were significantly associated with the presence of high RPR. RHI (odds ratio, 0.55; 95% confidence interval, 0.39-0.78; P=0.001) and ACE-I or ARB use (odds ratio, 3.22, 95% confidence interval, 1.07-9.65; P=0.04) were shown as the independently associated factor for high RPR among the significant variables in simple analysis. We also performed multivariable logistic regression analysis using the factors (age, body mass index, diabetes mellitus, estimated glomerular filtration rate, and Log 10 [fibrinogen]) that had been repeatedly reported to impact the high RPR group in several studies reported previously. 18,21-26 RHI and age were identified as an independent determinant of high RPR (RHI: odds ratio; 0.61; 95% confidence interval, 0.45-0.84; P=0.002, age: odds ratio, 1.06; 95% confidence interval, 1.00-1.12; P=0.04; Table 4 ). RHI was not associated with high-density lipoprotein cholesterol, hemoglobin A1c, or waist circumference (high-density lipoprotein cholesterol: r=0.09, P=0.39; hemoglobin A1c: r=−0.04, P=0.66; waist circumference: r=0.02, P=0.85). RHI was significantly associated with estimated glomerular filtration rate and high-sensitivity C-reactive protein (estimated glomerular filtration rate: r=0.18, P=0.04; high-sensitivity C-reactive protein: r=−0.30, P=0.003). RHI was also significantly associated with high RPR 208 by using the cutoff value of 208 PRU (Tables I-III in the online-only Data Supplement).
Association Between Endothelial Function and high RPR
We also analyzed the association in the 2 groups regarding the duration of clopidogrel treatment: the short-term loading group (≤7 days) and the long-term group (>7 days). RHI was the significant factor for high RPR in both the short-term loading and the long-term groups by methods using 2 significant factors (Table IV -VII in the online-only Data Supplement).
Cardiovascular Events in the high RPR and Non-high RPR Groups
The data of 103 patients were available for analyzing cardiovascular events. The follow-up period was 14 to 1340 days (mean: 657 days; median: 620 days). Overall, 17 cardiovascular events were recorded during the follow-up period ( Table VIII in the online-only Data Supplement). The time to first cardiovascular events in the high RPR group was nonsignificantly shorter than the non-high RPR group by Kaplan-Meier analysis (log-rank test: P=0.31; Figure I in the online-only Data Supplement). We also compared the cardiovascular outcomes by using the cutoff value of 208 PRU ( Table IX in 
In Vitro Experiments of Endothelial Function and Platelet Reactivity
Platelet reactivity of human platelet-rich plasma incubated with dysfunctional human coronary artery endothelial cells treated by nitro-l-arginine methyl ester was significantly higher than that incubated with normal human coronary artery endothelial cells without nitro-l-arginine methyl ester ( 
Discussion
This is the first study to demonstrate the significant effect of peripheral endothelial dysfunction on RPR after DAPT with aspirin and clopidogrel in patients with stable CAD who were confirmed to carry no CYP2C19 reduced-function allele, which is the most established factor for high RPR in clinical setting. 10, 12, 27 Clinical studies reported that high RPR after DAPT is associated with increased risk for cardiovascular events. 1-3 However, evidence for the association between intensive antiplatelet therapy for improvement of high RPR and prevention of cardiovascular events is still insufficient. 4, 5, 8 Therefore, to study the clinical importance of the pathogenesis of high RPR, we demonstrated here that endothelial dysfunction, assessed by measuring RHI, is an important and independent determinant of high RPR after DAPT in patients with stable CAD.
Clopidogrel is a prodrug that requires biotransformation by hepatic CYP enzymes into an activate metabolite. 9 Various factors, including variants of CYP genes and drug interaction, are associated with high RPR. [10] [11] [12] The association between high RPR after DAPT and CYP2C19 single-nucleotide polymorphisms has been thoroughly investigated, and the interactive Data are mean±SD, median [25th to 75th percentile range], or number (%). ACE-I indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin-II receptor blockers; BMI, body mass index; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; hs-Tn-T, high-sensitivity troponin T; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; OMI, old myocardial infarction; RPR, residual platelet reactivity; RHI, reactive hyperemia index; and SYNTAX score, the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score. effects of drugs metabolized by CYP2C19 enzyme have been well discussed. 28 The majority of Europeans and Americans lack the CYP2C19 reduced-function allele, 13, 14 and guidelines do not recommend genetic analysis, including CYP2C19, 15, 29 to estimate the cardiovascular risk after DAPT. Thus, the precise pathogenic mechanism of high RPR remains unknown, although several mechanisms have been proposed for platelet response to clopidogrel. These include CYP2C19 singlenucleotide polymorphisms, age, body mass index, diabetes mellitus, renal function, C-reactive protein, fibrinogen, and endothelial function. 18, [21] [22] [23] [24] [25] [26] In this study, we simultaneously measured peripheral endothelial function by RHI and evaluated RPR in a population lacking CYP2C19*2 or *3 loss-offunction allele, selected specifically to avoid the effects of this gene on platelet activity. The results identified peripheral endothelial dysfunction as a significant determinant of high RPR in patients with stable CAD.
Muller et al 18 reported the correlation between endothelial function and RPR using RH-PAT. In their study, all patients received long-term and relative high dose of aspirin treatment (160-325 mg) and a loading dose of clopidogrel (600 mg) ≥12 hours before RH-PAT. They did not compare RH-PAT value between high RPR and non-high RPR. Furthermore, they did not carefully assess or discuss the impacts of coronary risk factors, medications, and genetic polymorphisms on RPR. The results of our study were consistent with their data and further demonstrated a significant correlation between high RPR and lower RHI, independent of other coronary risk factors, medications, and genetic polymorphisms. In our study, high RPR was still observed in the long-term treatment with clopidogrel, and the duration of clopidogrel treatment did not affect the results. This might be because the present population was patients with stable CAD.
Patients with high RPR were significantly older, more likely hypertensive, and had higher BNP level compared with the non-high RPR group. Furthermore, RHI was significantly lower in the high RPR group than in the nonhigh RPR group. Multivariable logistic regression analysis demonstrated that the use of ACE-I or ARB and RHI were 2 factors that significantly correlated with high RPR. There was no significant association between ACE-I or ARB and high RPR 208 in the case of using the cutoff value of 208 PRU (Table I -III in the online-only Data Supplement). This result indicated that ACE-I or ARB use was not the consistently correlated factor for high RPR 208 . We consider that it might be just observed as the chance phenomenon that patients of the high RPR were more frequently treated with ACE-I or ARB. Advanced age and endothelial dysfunction are independently associated with high RPR. A previous study reported that aging per se correlated with high RPR. 30 However, elderly patients frequently experience bleeding complications during antiplatelet therapy. Several studies demonstrated that high RPR itself was treatable and adjustable by increasing the dose of clopidogrel 4, 5 ; however, in the clinical setting, it is practically difficult to subject elderly patients to aggressive antiplatelet therapy during DAPT. 7 Furthermore, in the previous studies, the intensification of antiplatelet therapy by high-dose clopidogrel according to platelet reactivity did not improve clinical outcomes. 4, 5 Considering together, there is a need to develop a new clinical approach rather than increasing the dose of antiplatelet medications for the treatment of high RPR in future cardiovascular practice.
Endothelial function plays important roles in the maintenance of vascular tone, thrombosis, platelet adhesion, and vasculature-blood cell homeostasis, and the impaired endothelial function reflects early atherosclerotic changes. [31] [32] [33] Furthermore, atherosclerogenesis involves platelet aggregation. Chronic inflammation occurs at sites of atherosclerogenesis, which also includes recruitment of platelets to the sites of endothelial injury, and activated platelet could further evoke plaque development. Endothelial dysfunction can also predict future cardiovascular events in patients with CAD. 34 Furthermore, most plaque disruption occurs in lesions that contain a soft, lipid-rich core covered by a thin, inflamed fibrous cap, which often accompanies dysfunctional endothelium. In patients with CAD, endothelial dysfunction would be a key component of plaque vulnerability, possibly leading to the occurrence of cardiovascular complications. Endothelial function could be improved by appropriate medications and lifestyle interventions. 35, 36 One previous study indicated that platelet reactivity improved after a reduction in hemoglobin A1c in patients with type 2 diabetes mellitus. 37 Statins also improve platelet reactivity in vitro. 38 Treatment of coronary risk factors by optimal medications, with subsequent improvement of endothelial dysfunction, could attenuate enhanced platelet aggregation and reduce cardiovascular events after PCI; however, the clinical evidence is not strong enough at present, and further investigation is encouraged. The precise molecular mechanism of endothelial dysfunction in patients with high RPR after DAPT remains unknown. Previous study demonstrated that platelet-derived nitric oxide inhibits platelet aggregation by increasing intraplatelet cGMP. Ikeda et al 39 demonstrated that the platelet-derived nitric oxide formation correlated with the number of risk factors. Our results of in vitro experiments demonstrated that endothelial cells could play a role in the nitric oxide-mediated regulation of platelet activation. A previous study also demonstrated that endothelial cell-derived nitric oxide plays a role in platelet aggregation. 40 We consider that both endothelial cell-derived nitric oxide and platelet-derived nitric oxide might be important in the regulation of platelet reactivity. However, we could not conclude the correlation between endothelial cell-derived nitric oxide and platelet-derived nitric oxide in the regulation of platelet reactivity in the present study because we did not measure nitric oxide levels in the present population. Further investigations are needed.
Study Limitations
Interpretation of the results of the present study is limited by the small sample size and single-center study. Age, prevalence of hypertension, and BNP value were different between the 2 study groups. Multivariable logistic regression analysis did not identify hypertension and BNP to be associated with high RPR. The effects of advanced age and ACE-I or ARB use could not be excluded. Because the population was small, we could not conclude the significant difference in the clinical outcomes between the non-high RPR group and the high RPR group in the present study. Further clinical trials in larger population are required.
Conclusions
In patients with stable CAD who lack the CYP2C19*2 or *3 loss-of-function allele, peripheral endothelial function was significantly impaired in those with high RPR. Endothelial dysfunction is an important and modifiable factor associated independently with high RPR after DAPT with aspirin and clopidogrel.
